1,839
Views
2
CrossRef citations to date
0
Altmetric
Clinical Study

Tip lesion variant of primary focal and segmental glomerulosclerosis: clinicopathological analysis of 20 cases

, , , &
Pages 858-865 | Received 21 Dec 2014, Accepted 18 Mar 2015, Published online: 10 Apr 2015

Figures & data

Table 1. Clinical and laboratory features of the 20 cases of FSGS-GTL.

Figure 1. Sclerosed capillaries are occluded by foamy macrophages (arrows); the uninvolved parts of the glomeruli have patent capillary lumina, normal mesangium and cellularity (a: H&E × 400; b: Jones' methenamine silver × 400 (a and b depict the same glomerulus)).

Figure 1. Sclerosed capillaries are occluded by foamy macrophages (arrows); the uninvolved parts of the glomeruli have patent capillary lumina, normal mesangium and cellularity (a: H&E × 400; b: Jones' methenamine silver × 400 (a and b depict the same glomerulus)).

Figure 2. Sclerotic segment in each glomerulus is minute and is noted mainly by the adhesion of loop to Bowman's capsule (arrows) (a: PAS × 400; b: Masson trichrome × 400 (a and b depict the same glomerulus)).

Figure 2. Sclerotic segment in each glomerulus is minute and is noted mainly by the adhesion of loop to Bowman's capsule (arrows) (a: PAS × 400; b: Masson trichrome × 400 (a and b depict the same glomerulus)).

Figure 3. Tip lesions with hyalinosis (arrows) (a: H&E × 400; b: Periodic acid methenamine silver ×400 (a and b depict the same glomerulus)).

Figure 3. Tip lesions with hyalinosis (arrows) (a: H&E × 400; b: Periodic acid methenamine silver ×400 (a and b depict the same glomerulus)).

Figure 4. Glomeruli with mesangial expansion and cellularity in addition to tip lesion (a and b: PAS × 400).

Figure 4. Glomeruli with mesangial expansion and cellularity in addition to tip lesion (a and b: PAS × 400).

Table 2. Histopathological findings in the renal biopsy specimens.

Table 3. Characteristics of patients with FSGS-GTL and comparison between patients showing partial remission, complete remission with recurrence and complete remission without recurrence.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.